Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
October 24, 2025
Not intended for U.S. and UK Media
Bayer’s Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause
September 22, 2025
Not intended for US and UK Media
Bayer first company to advance cell therapy as well as gene therapy against Parkinson’s disease
September 18, 2025
Not intended for U.S. and UK Media
New drug application for gadoquatrane accepted for review in China
Discover More
